The US government's National Institutes of Health (NIH) will award at least 5 research grants studying how ibogaine changes the brain and how scientists might create similar drugs without the psychedelic effects. This matters because it signals that federal science institutions see real promise in ibogaine as a medicine, not just a drug of abuse.
Clear mechanistic findings with translational potential reliably attract R01 funding. The juvenile plasticity angle provides multiple publishable follow-up vectors. However, 5 funded studies is a high bar given NIH funding rates (~20%) and the 2-year window. Non-hallucinogenic analogue work is highly incentivized by NIDA. Confidence slightly reduced from original due to funding environment uncertainty and the specificity of the '5 studies' threshold.